Do you want to read an article? Please log in or register.
Association Between Personality Traits and Onabotulinumtoxin A Response in Patients With Chronic Migraine
Migraine and Headache
Related content
RECOMMENDED
Migraine and Headache
The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response
★ 2
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Cephalalgia.
Brandes JL, Diener HC, Dolezil D, Freeman MC, McAllister PJ, Winner P, Klatt J, Cheng S, Zhang F, Wen S, Ritter S, Lenz RA, Mikol DD
doi: 10.1177/0333102419894559.
Migraine and Headache
CGRP and PTX3 as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine: An Observational Study
Headache.
Domínguez C, Vieites-Prado A, Pérez-Mato M, Sobrino T, Rodríguez-Osorio X, López A, Campos F, Martínez F, Castillo J, Leira R
doi: 10.1111/head.13211.
Migraine and Headache
Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study
Headache
Spierings ELH, Ning X, Ramirez Campos V, Cohen JM, Barash S, Buse DC
doi: 10.1111/head.14196
Migraine and Headache
Onabotulinumtoxin-A in Chronic Migraine: Should Timing and Definition of Non-Responder Status Be Revised? Suggestions From a Real-Life Italian Multicenter Experience
Headache.
Vernieri F, Paolucci M, Altamura C, Pasqualetti P, Mastrangelo V, Pierangeli G, Cevoli S, D'Amico D, Grazzi L
doi: 10.1111/head.13617.
Migraine and Headache
Living with chronic migraine: a qualitative study on female patients' perspectives from a specialised headache clinic in Spain
BMJ Open.
Palacios-Ceña D, Neira-Martín B, Silva-Hernández L, Mayo-Canalejo D, Florencio LL, Fernández-de-Las-Peñas C, García-Moreno H, García-Azorín D, Cuadrado ML
doi: 10.1136/
Migraine and Headache
The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response
Headache.
Broessner G, Reuter U, Bonner JH, Dodick DW, Hallström Y, Picard H, Zhang F, Lenz RA, Klatt J, Mikol DD
doi: 10.1111/head.13929.
Migraine and Headache
Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine
Cephalalgia.
Brandes JL, Kudrow D, Yeung PP, Sakai F, Aycardi E, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y
doi: 10.1177/0333102419885905.
Migraine and Headache
The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response
Headache
Broessner G, Reuter U, Bonner JH, Dodick DW, Hallström Y, Picard H, Zhang F, Lenz RA, Klatt J, Mikol DD
doi: 10.1111/head.13929
Migraine and Headache
A prospective pilot study of the effect on catecholamines of mindfulness training vs pharmacological prophylaxis in patients with chronic migraine and medication overuse headache
Cephalalgia.
Grazzi L, Raggi A, D'Amico D, Sansone E, Leonardi M, Andrasik F, Gucciardi A, Guido D, D'Andrea G
doi: 10.1177/0333102418801584.